/ Ways2Capital : Cipla Launches Hepatitis B Vaccine In India ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Friday, 17 February 2017

Cipla, a global pharmaceutical company, announced that it has launched adult Hepatitis B vaccine in India, under a co-exclusive agreement with Serum Institute of India Private Limited (SII). Cipla will be marketing the vaccine for adults while SII will market it for adults and children.

The stock of the company is trading with gains, and in the last one year, the stock has given a return of 15%. ICICI Prudential Mutual Fund is the top fund house which has invested in the stock of the company. Serum Institute of India Private Limited is the world's second largest vaccine manufacturer pertaining to number of doses manufactured and supplied to more than 140 countries.

Cipla Ltd is currently trading at Rs 594.75, up by Rs 11.35 or 1.95% from its previous closing of Rs 583.4 on the BSE. The scrip opened at Rs 585 and has touched a high and low of Rs 596.25 and Rs 581.7 respectively. So far 1027618(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 46932.88 crore.

The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 621.9 on 06-Feb-2017 and a 52 week low of Rs 458.25 on 25-May-2016. Last one week high and low of the scrip stood at Rs 594 and Rs 571.15 respectively. The promoters holding in the company stood at 36.73 % while Institutions and Non-Institutions held 34.92 % and 26.33 % respectively. The stock is currently trading above its 50 DMA.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717